Welcome to our dedicated page for CERo Therapeutics SEC filings (Ticker: CERO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Clinical-stage biotechnology companies generate SEC filings that reveal critical information about their financial runway and operational progress. For CERo Therapeutics Holdings (CERO), these documents provide transparency into how the company allocates capital toward its chimeric engulfment receptor research program while navigating the regulatory pathway for CER-1236.
Quarterly and Annual Reports (10-Q and 10-K filings) detail CERo's research and development expenditures, cash position, and operational burn rate—metrics essential for evaluating how long the company can fund clinical trials before requiring additional financing. These filings also disclose clinical trial progress, partnership arrangements, and risk factors specific to early-stage drug development.
Material Event Disclosures (8-K filings) announce significant developments as they occur: financing transactions, clinical milestones, patent developments, and changes in corporate structure. For a company in Phase 1 trials, 8-K filings often contain the most time-sensitive information about regulatory interactions and trial progress.
Registration Statements (S-1, S-3) and Prospectus Supplements (424B3) document equity offerings and financing activities. Clinical-stage biotechs frequently raise capital through public offerings, and these filings specify terms, use of proceeds, and dilution impact on existing shareholders.
Proxy Statements (DEF 14A) disclose executive compensation, board composition, and shareholder voting matters. For investors evaluating management alignment with shareholder interests, these documents provide essential governance information.
Our AI-powered summaries help you quickly understand what each CERo Therapeutics filing contains without reading dozens of pages of regulatory language. Track insider transactions through Form 4 filings to see when executives and directors buy or sell shares.
Cero Therapeutics Holdings, Inc. director Rolfe Lindsey reported receiving a stock option award. On January 7, 2026, he was granted a Stock Option (Right to Buy) covering 690,900 shares of common stock. The option has a conversion or exercise price of $0.055 per share, becomes exercisable on January 7, 2026, and carries an expiration date of January 6, 2036. Following this grant, Lindsey beneficially owned 690,900 derivative securities directly.
Cero Therapeutics Holdings, Inc. reported that director Kathleen LaPorte received a stock option grant. On January 7, 2026, she was awarded a Stock Option (Right to Buy) covering 690,900 shares of common stock with a conversion or exercise price of $0.055 per share. The option is listed as exercisable on January 7, 2026 and expires on January 6, 2036. Following this grant, LaPorte is shown as directly beneficially owning 690,900 derivative securities linked to the company’s common stock.
Cero Therapeutics Holdings, Inc. reported that Chief Development Officer Kristen Pierce received a grant of stock options on 01/07/2026. The award covers 1,612,099 stock options, each representing the right to buy one share of common stock at an exercise price of $0.055 per share. Following this grant, Pierce beneficially owns 1,612,099 derivative securities, all held in direct ownership form.
CERO Therapeutics Holdings, Inc. reported that director Shami Patel received a stock option grant. On January 7, 2026, Patel was awarded an option to buy 690,900 shares of CERO common stock at an exercise price of $0.055 per share. The option is first exercisable on January 7, 2026 and expires on January 6, 2036. After this grant, Patel beneficially owns stock options covering 690,900 shares, held as a direct ownership position.
Cero Therapeutics Holdings director reports large stock option award
Brian G. Atwood, a director of Cero Therapeutics Holdings, Inc., reported receiving a stock option covering 1,612,099 shares of the company’s common stock. The option has an exercise price of $0.055 per share, meaning he can buy up to that number of shares at this fixed price.
The option became exercisable on January 7, 2026 and is scheduled to expire on January 6, 2036, giving a 10‑year exercise window. Following this transaction, Atwood beneficially owns 1,612,099 derivative securities in the form of this stock option, which is reported as held directly.
Cero Therapeutics Holdings, Inc. reported that Chairman and CEO Christopher B. Ehrlich received a large stock option grant. On January 7, 2026, he was awarded a stock option to buy 4,530,997 shares of common stock at an exercise price of $0.055 per share. The option is exercisable from January 7, 2026 and expires on January 6, 2036. Following this grant, he beneficially owns 4,530,997 derivative securities, held as a direct ownership position, and there was no cash price paid for the option itself.
Cero Therapeutics Holdings, Inc. director Michael Byrnes received a grant of stock options on January 7, 2026. The award covers 690,900 stock options, each giving the right to buy one share of common stock at an exercise price of $0.055 per share. These options are held as direct ownership and are exercisable starting January 7, 2026, with an expiration date of January 6, 2036. The filing reports this derivative award and the resulting beneficial ownership of 690,900 derivative securities after the transaction.
Cero Therapeutics Holdings, Inc. granted its Chief Financial Officer, Andrew Kucharchuk, a stock option on January 7, 2026. The option gives the right to buy 1,162,099 shares of common stock at an exercise price of $0.055 per share. The option is listed as exercisable beginning January 7, 2026 and expires on January 6, 2036. Following this grant, Kucharchuk is reported as directly beneficially owning 1,162,099 derivative securities of this type.
CERO Therapeutics Holdings, Inc. has filed a prospectus supplement tied to its Form S-1 registration statement covering 729,596,950 shares of common stock, updating the related prospectus with information from a new Form 8-K.
The Form 8-K notes that the company has released an investor presentation for use in meetings and issued a press release titled “CERo Therapeutics Provides Clinical Update on Phase 1 Trial of CER-1236 in AML (CertainT-1) Highlighting Key Safety Data and Platelet Transfusion-Free Interval Observed in a Patient with Myelodysplastic Syndrome/AML.” The common stock trades on OTCQB under “CERO” and the public warrants trade on OTCID under “CEROW.”
CERo Therapeutics Holdings, Inc. filed a current report describing new investor and clinical communications. The company furnished an updated corporate presentation as an exhibit, which it plans to use in meetings with investors, analysts and others. This presentation is furnished rather than filed, meaning it is not automatically subject to certain Exchange Act liability provisions.
The company also issued a press release titled “CERo Therapeutics Provides Clinical Update on Phase 1 Trial of CER-1236 in AML (CertainT-1) Highlighting Key Safety Data and Platelet Transfusion-Free Interval Observed in a Patient with Myelodysplastic Syndrome/AML.” The press release and the presentation are included as exhibits, giving readers access to the latest clinical update and investor materials.
FAQ
What is the current stock price of CERo Therapeutics (CERO)?
What is the market cap of CERo Therapeutics (CERO)?
